Accueil>>Signaling Pathways>> Cell Cycle/Checkpoint>> G2/M>>NSC 756093

NSC 756093

Catalog No.GC49412

NSC 756093 est un puissant inhibiteur de l'interaction GBP1:PIM1. NSC 756093 peut potentiellement inverser la résistance au paclitaxel. NSC 756093 peut être utilisé pour la recherche sur le cancer de l'ovaire.

Products are for research use only. Not for human use. We do not sell to patients.

NSC 756093 Chemical Structure

Cas No.: 1629908-92-4

Taille Prix Stock Qté
1 mg
46,00 $US
En stock
5 mg
150,00 $US
En stock
10 mg
278,00 $US
En stock
25 mg
636,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

NSC 756093 is an inhibitor of the protein-protein interaction between guanylate binding protein 1 (GBP1) and the serine/threonine kinase Pim-1.1 It binds to GBP1-Pim-1 (Kd = 38 nM) and inhibits the interaction by 65% when used at a concentration of 100 nM. NSC 756093 enhances radiation-induced cytotoxicity in FaDu hypopharyngeal carcinoma cells (IC50 = 496 nM), as well as induces apoptosis and cell cycle arrest at the G2/M phase in the same cells.2

1.Andreoli, M., Persico, M., Kumar, A., et al.Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cellsJ. Med. Chem.57(19)7916-7932(2014) 2.Resendez, A., Tailor, D., Graves, E., et al.Radiosensitization of head and neck squamous cell carcinoma (HNSCC) by a podophyllotoxinACS Med. Chem. Lett.10(9)1314-1321(2019)

Avis

Review for NSC 756093

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NSC 756093

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.